Related Experiment Videos
Genotoxicity screening: the slow march to the future.
1Faculty of Life Sciences, The University of Manchester, G10, Jackson's Mill, PO Box 88, Sackville Street, Manchester, M60 1QD, UK.
Expert Opinion on Drug Metabolism & Toxicology
|August 23, 2006
Summary
High-throughput screening (HTS) is advancing genetic toxicology testing in drug development. These new methods promise to reduce costs by identifying undesirable compounds earlier in the drug discovery process.
Area of Science:
- Pharmacology
- Toxicology
- Genetics
Background:
- Genetic toxicology testing is crucial in drug discovery and development.
- Traditional methods are being enhanced by high-throughput screening (HTS) technologies.
- Validation studies and data analysis support the integration of HTS into decision-making processes.
Purpose of the Study:
- To review current genetic toxicology methodologies and HTS approaches.
- To compare the predictive accuracy of HTS strategies and regulatory tests for carcinogenesis.
- To evaluate the impact of false-positive and false-negative results at various developmental stages.
Main Methods:
- Overview of established genetic toxicology assays.
- Introduction to selected high-throughput screening methodologies.
- Comparative analysis of predictive performance for carcinogenicity.
Main Results:
- HTS methodologies are increasingly adopted in genetic toxicology.
- Comparisons highlight the predictive capabilities of screening strategies versus regulatory test batteries.
- The significance of accurate (and inaccurate) calls in compound development is examined.
Conclusions:
- HTS offers a promising future for genetic toxicology, akin to advancements in ADME-Tox.
- The adoption of HTS is expected to decrease costs associated with late-stage compound failure.
- Integrating HTS can optimize drug development by identifying problematic compounds earlier.